These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 2665909

  • 1. Urine citrate and renal stone disease.
    Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG.
    CMAJ; 1989 Aug 01; 141(3):217-21. PubMed ID: 2665909
    [Abstract] [Full Text] [Related]

  • 2. Citrate and renal calculi: an update.
    Pak CY.
    Miner Electrolyte Metab; 1994 Aug 01; 20(6):371-7. PubMed ID: 7783699
    [Abstract] [Full Text] [Related]

  • 3. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY, Sakhaee K, Fuller CJ.
    Trans Assoc Am Physicians; 1983 Aug 01; 96():294-305. PubMed ID: 6679957
    [Abstract] [Full Text] [Related]

  • 4. Effects of citrate on the different phases of calcium oxalate crystallization.
    Tiselius HG, Berg C, Fornander AM, Nilsson MA.
    Scanning Microsc; 1993 Mar 01; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
    [Abstract] [Full Text] [Related]

  • 5. [Citrate and kidney stones].
    Osther PJ.
    Ugeskr Laeger; 1993 Nov 22; 155(47):3835-9. PubMed ID: 8256384
    [Abstract] [Full Text] [Related]

  • 6. Body size and 24-hour urine composition.
    Taylor EN, Curhan GC.
    Am J Kidney Dis; 2006 Dec 22; 48(6):905-15. PubMed ID: 17162145
    [Abstract] [Full Text] [Related]

  • 7. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion.
    Domrongkitchaiporn S, Stitchantrakul W, Kochakarn W.
    Am J Kidney Dis; 2006 Oct 22; 48(4):546-54. PubMed ID: 16997050
    [Abstract] [Full Text] [Related]

  • 8. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE, Odvina CV, Wuermser LA, Pak CY.
    J Urol; 2007 Jun 22; 177(6):2179-84. PubMed ID: 17509313
    [Abstract] [Full Text] [Related]

  • 9. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, Suwantrai S, Noppawinyoowong C, Maskasame S, Sriboonlue P.
    J Med Assoc Thai; 2004 Mar 22; 87(3):255-63. PubMed ID: 15117041
    [Abstract] [Full Text] [Related]

  • 10. [The significance of citrate excretion and calcium/citrate quotients in urine in patients with calcium calculi].
    Hofbauer J, Höbarth K, Zechner O.
    Z Urol Nephrol; 1990 Nov 22; 83(11):597-602. PubMed ID: 2100085
    [Abstract] [Full Text] [Related]

  • 11. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B.
    Ther Umsch; 2003 Feb 22; 60(2):79-87. PubMed ID: 12649986
    [Abstract] [Full Text] [Related]

  • 12. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML, Chi T, Eisner BH, Shami G, Gentle DL.
    J Urol; 2009 Mar 22; 181(3):1140-4. PubMed ID: 19152919
    [Abstract] [Full Text] [Related]

  • 13. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N, Jansen B, Hesse A.
    Urol Res; 2002 Oct 22; 30(5):336-41. PubMed ID: 12389124
    [Abstract] [Full Text] [Related]

  • 14. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment.
    Caudarella R, Vescini F.
    Arch Ital Urol Androl; 2009 Sep 22; 81(3):182-7. PubMed ID: 19911682
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of factors involved in calcium stone formation.
    Abraham PA, Smith CL.
    Miner Electrolyte Metab; 1987 Sep 22; 13(3):201-8. PubMed ID: 3627051
    [Abstract] [Full Text] [Related]

  • 16. Alkaline citrate in prevention of recurrent calcium oxalate stones.
    Berg C.
    Scand J Urol Nephrol Suppl; 1990 Sep 22; 130():1-83. PubMed ID: 2291093
    [Abstract] [Full Text] [Related]

  • 17. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A, Pizá P, García-Raja A, Grases F, Costa-Bauzá A, Prieto RM.
    Arch Esp Urol; 1999 Apr 22; 52(3):305-10. PubMed ID: 10371752
    [Abstract] [Full Text] [Related]

  • 18. Alkali absorption and citrate excretion in calcium nephrolithiasis.
    Sakhaee K, Williams RH, Oh MS, Padalino P, Adams-Huet B, Whitson P, Pak CY.
    J Bone Miner Res; 1993 Jul 22; 8(7):789-94. PubMed ID: 8352061
    [Abstract] [Full Text] [Related]

  • 19. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
    Hassani MA, Hennequin C, Lacour B, Daudon M.
    Prog Urol; 2005 Sep 22; 15(4):650-5. PubMed ID: 16459680
    [Abstract] [Full Text] [Related]

  • 20. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate).
    Conte A, Pizá P, García-Raja A.
    Arch Esp Urol; 1999 Sep 22; 52(1):94-9. PubMed ID: 10101897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.